Tech Company Financing Transactions
Prime Medicine Funding Round
Prime Medicine secured a $24 million venture capital round on 7/16/2025. Investors included Cystic Fibrosis Foundation.
Transaction Overview
Company Name
Announced On
7/16/2025
Transaction Type
Venture Equity
Amount
$24,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
21 Erie St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can search and replace to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Keith Gottesdiener
Chief Scientific Officer
Jeremy Duffield
Co-Founder
Andrew Anzalone
VP - General Counsel
Karen Brown
VP - Operations
Meredith Goldwasser
Browse more venture capital transactions:
Prev: 7/16/2025: Rwazi venture capital transaction
Next: 7/16/2025: FlyGuys venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs